CY1108734T1 - Αναπτυξη αντισωματων ειδικων για hcv - Google Patents

Αναπτυξη αντισωματων ειδικων για hcv

Info

Publication number
CY1108734T1
CY1108734T1 CY20091100101T CY091100101T CY1108734T1 CY 1108734 T1 CY1108734 T1 CY 1108734T1 CY 20091100101 T CY20091100101 T CY 20091100101T CY 091100101 T CY091100101 T CY 091100101T CY 1108734 T1 CY1108734 T1 CY 1108734T1
Authority
CY
Cyprus
Prior art keywords
hcv
antibodies
development
specific antibodies
nob
Prior art date
Application number
CY20091100101T
Other languages
Greek (el)
English (en)
Inventor
Michael Houghton
Mark Selby
Sergio Abrignani
Jens Heile
Hagan Derek O´
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1108734T1 publication Critical patent/CY1108734T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20091100101T 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv CY1108734T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823499P 1999-12-01 1999-12-01
US18505500P 2000-02-25 2000-02-25
EP00993586A EP1233782B1 (en) 1999-12-01 2000-12-01 Eliciting hcv-specific antibodies

Publications (1)

Publication Number Publication Date
CY1108734T1 true CY1108734T1 (el) 2014-04-09

Family

ID=26863907

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100101T CY1108734T1 (el) 1999-12-01 2009-01-27 Αναπτυξη αντισωματων ειδικων για hcv

Country Status (12)

Country Link
US (3) US7329408B2 (https=)
EP (1) EP1233782B1 (https=)
JP (1) JP2004500366A (https=)
AT (1) ATE413190T1 (https=)
AU (1) AU5442501A (https=)
CA (1) CA2393251C (https=)
CY (1) CY1108734T1 (https=)
DE (1) DE60040755D1 (https=)
DK (1) DK1233782T3 (https=)
ES (1) ES2319727T3 (https=)
PT (1) PT1233782E (https=)
WO (1) WO2001047551A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
SK15762003A3 (sk) * 2001-06-29 2005-01-03 Chiron Corporation Kompozícia vakcíny HCV E1E2
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
WO2004065578A2 (en) * 2003-01-14 2004-08-05 Chiron Corporation Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles
WO2004071414A2 (en) * 2003-02-05 2004-08-26 Genzyme Corporation Therapeutic anti-hcv (al9) compounds
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
JP5557415B2 (ja) * 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
CA2566725A1 (en) * 2004-05-17 2005-12-01 Chiron Corporation Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
US20080154210A1 (en) 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
DE602005026545D1 (de) * 2004-08-24 2011-04-07 Tokyo Metropolitan Org Med Res Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US8178086B2 (en) * 2006-01-04 2012-05-15 Novartis Vaccines And Diagnostics, Inc. Activation of HCV specific T cells
US20100291545A1 (en) 2007-07-25 2010-11-18 Takaji Wakita Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
EP2495256A4 (en) 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
CN104324373B (zh) * 2010-11-26 2018-10-09 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5471330A (en) 1993-07-29 1995-11-28 Honeywell Inc. Polysilicon pixel electrode
DE69534296T2 (de) * 1994-07-29 2006-04-27 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
DE69608122T3 (de) * 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
DE69841015D1 (de) * 1997-05-06 2009-09-10 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
WO1999004010A1 (en) * 1997-07-18 1999-01-28 Connaught Laboratories Limited Nucleic acid vaccines encoding g protein of respiratory syncytial virus
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
US20080095800A1 (en) 2008-04-24
AU5442501A (en) 2001-07-09
EP1233782A2 (en) 2002-08-28
ES2319727T3 (es) 2009-05-12
PT1233782E (pt) 2009-02-13
CA2393251A1 (en) 2001-07-05
DE60040755D1 (de) 2008-12-18
US20110159039A1 (en) 2011-06-30
CA2393251C (en) 2012-01-31
WO2001047551A2 (en) 2001-07-05
WO2001047551A3 (en) 2002-03-14
JP2004500366A (ja) 2004-01-08
US20020002272A1 (en) 2002-01-03
DK1233782T3 (da) 2009-02-09
ATE413190T1 (de) 2008-11-15
US7329408B2 (en) 2008-02-12
EP1233782B1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
CY1108734T1 (el) Αναπτυξη αντισωματων ειδικων για hcv
DK0450931T3 (da) Kombinationer af hepatitis C-virus (HCV)-antigener til anvendelse i immunoassays for anti-HCV-antistoffer
BRPI0111682B8 (pt) suporte sólido de imunoensaio, kit de teste de imunodiagnóstico, métodos de produção de um suporte sólido de imunoensaio, e de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e, uso de um suporte sólido de imunoensaio
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
IL152825A0 (en) Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
WO2001098333A3 (en) Modification of hepatitis b core antigen
ATE17320T1 (de) Impfstoff, therapie gegen nicht-a nicht-b virale hepatitis und verfahren zur herstellung desselben.
NO985339L (no) Humane B-celleantigener og beslektede reagenser
NO20004413D0 (no) HIV peptider, antigener, vaksine, blandinger, immunoassay, kit og en fremgangmÕte for pÕvisning av antistoffer som blir infusert av HIV
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DK0623169T3 (da) Hepatitis E virus og fremgangsmåde
DE69531235D1 (de) Säugetier - Expressionssysteme für Hüllenprotingene des Hepatitit - C - Virus
EP1301208A4 (en) Vaccine
NO20051715L (no) HCV assay
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
RU2008114385A (ru) ИНДУКТОР СЕКРЕТОРНЫХ АНТИТЕЛ IgA И IgG
EP0339668A3 (en) Hepatitis a virus antigen
FI923020A0 (fi) Inte a inte b-sekvenser.
DK0556320T3 (da) Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
DK230090A (da) Peptider
DE68918440D1 (de) Verfahren zur transformation von menschlichen b-lymphocyten.
WO2003014728A1 (fr) Medicaments contre l'hepatite c
WO2002000252A3 (en) Non-human animal models of tolerance to hepatitis c virus immunogenes